Zacks: Oncobiologics Inc (ONS) Receives Average Rating of “Hold” from Analysts

Shares of Oncobiologics Inc (NASDAQ:ONS) have received an average broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation. Oncobiologics’ rating score has declined by 200% from 90 days ago as a result of a number of analysts’ ratings changes.

Zacks has also given Oncobiologics an industry rank of 183 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

A number of brokerages have recently issued reports on ONS. ValuEngine raised Oncobiologics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Barclays lowered Oncobiologics from an “overweight” rating to an “equal weight” rating in a research report on Monday, January 29th.

Shares of Oncobiologics stock traded down $0.01 on Friday, reaching $0.93. 3,874 shares of the company were exchanged, compared to its average volume of 41,695. The company has a quick ratio of 0.49, a current ratio of 0.49 and a debt-to-equity ratio of -0.01. Oncobiologics has a fifty-two week low of $0.78 and a fifty-two week high of $2.80.

Oncobiologics (NASDAQ:ONS) last announced its earnings results on Wednesday, February 14th. The company reported ($0.28) earnings per share (EPS) for the quarter. The firm had revenue of $0.77 million during the quarter.

TRADEMARK VIOLATION NOTICE: This story was first reported by Week Herald and is the property of of Week Herald. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Get a free copy of the Zacks research report on Oncobiologics (ONS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with's FREE daily email newsletter.

Leave a Reply